|

SYS6010 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1
  • CSPC Megalith Biopharmaceutical Co.,Ltd.1

Indications

  • Cancer2
  • EGFR-mutated Locally Advanced or Metastatic NSCLC1
  • Advanced Solid Tumors1
  • Lung Cancer1

Other2 trials

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
Phase 1/2
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.